Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
I see Avidimab as a pre-clinical asset.
As we know it is currently involved in SCOPE. If we assume that iSCIB1+ takes over from SCIB1 and provides above the assumed 70% ORR and a durable response, we must accept that Avidimabs role is not stand alone in that instance. It will have become part of the package iSCIB1+, which imo would be successfully demonstrated as THE stand alone asset. So Avidimab plus something else makes a stand alone asset = Avidimab makes a hybrid but is not the actual asset.
So my question is, despite having a significant role in say a SEAGEN or Scancell trial, why on earth would either company water down the subject of there own successful clinical asset (SEA-CD40 or iSCIB1+) by saying that it was due in part to Avidimab? Remember the objective of the trial being to prove the stand alone asset, not the delivery method etc etc.It is wholly more likely in my view that both SEAGEN and Scancell would be encouraged but still be unable to prove the exact role Avidimab plays without a robust trial of its own.
Finally, it may well become important for the regulatory bodies to understand the role Avidimab plays... This is because if it is not clearly defined, it could be used to boost poor drug candidates results. If for instance FDA were able to understand definitively what it does, then it would make distinguishing trial results clearer.
Conclusion: Avidimab needs its own trials. It could prove itself to be a successful mab in its own right; a successful asset in its own right. Maybe more likely in combination? This would mean it could be worth billions. But until then, the only way forward is if there are brave maverick entrepreneurial types willing to take it on. Or the more sensible types that will give it a six month assessment and maybe a milestone deal?
Anyway, these are not my definitive thoughts, just spit balling so feel free to tell me I am wrong!
Hi Matt,
Think most here would agree that the share price is in the doldrums. We were lucky to get funding imo. Only some of the very best AIM prospects will survive this awful market. Scancell had the sense to grab funding with both hands. That is extremely positive imo as it protects all our investments.
Diggers,
My understanding is that the assay and testing landscape is evolving so quickly that Angle feel it important to choose the right way to test and present the ovarian and prostate assays.
Important to remember that these stored samples are extremely precious and I believe that Angle have one shot at analysing and presenting these results to market.
Therefore the must chose which NGS system will give Angle the best chance of commercialisation. If of course they test the samples this way.
I see no better explanation but happy to stand corrected.
ATB
Hi Violindog,
Just look at the latest presentation. Scancell are commercialising; selling glymab targets etc. This may well include a milestone from GenMab. This is about putting money on the bottom line and adding real tangible value to the business, not just about making shareholders feel calmer. That is just a pleasant after effect. Also we must remember that there may be some technical development required in taking SC129 target to the clinic. Apparently GenMab are whizzo at these things so fingers crossed!
Think they were 70 NK in September last year which was before they announced the two sets of trial results should be expected around March this year. The share price got to 120 and the mesothelioma results tipped them to 150. Dropped back to 120 last night. So anticipation played a big part in their share price rise imo.
Thanks JB1,
I am going to check the Scancell results presentation as I think Lindy said INITIUM had something like a 57% ORR so she was not too concerned about it. I have tried to find previous ORR readouts for INITIUM and have not been able to find any. In any case, if it was indeed high fifties or early sixties then that would have been might close to CI's alone... Unfortunately they have not been able to demonstrate a difference by adding UV1 to CI's against CI's alone. That is very sad indeed for patients. The positive for us is that we now have an open goal so to speak and it looks like team Scancell has it's shooting boots on!
Cannot see why people would sell here unless they are sheep that are seriously under researched.
ATB
Https://angleplc.com/about-us/events/
Press link